[Pembrolizumab (Keytruda®) associated ocular hypotony]
- PMID: 36725738
- DOI: 10.1007/s00347-023-01808-6
[Pembrolizumab (Keytruda®) associated ocular hypotony]
References
Literatur
-
- Roberts K, Culleton V, Lwin Z, O’Byrne K, Hughes BG (2017) Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities. Asia Pac J Clin Oncol 13(4):277–288. https://doi.org/10.1111/ajco.12698 - DOI - PubMed
-
- Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA (2018) Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects. Retina 38(6):1063–1078. https://doi.org/10.1097/iae.0000000000002181 - DOI - PubMed
-
- https://www.ema.europa.eu/en/documents/product-information/keytruda-epar... . Zugegriffen: 15. Dez. 2022
-
- Mihailovic N, Dyballa J, Herz S, Fluck M, Alnawaiseh M, Merté RL, Eter N (2020) Vogt-Koyanagi-Harada-like uveitis under immune checkpoint inhibitor treatment for metastasized malignant melanoma. Ophthalmologe 117(5):467–471. https://doi.org/10.1007/s00347-019-00963-z - DOI - PubMed
-
- Wang Q, Thau A, Levin AV, Lee D (2019) Surv ocular hypotony: a comprehensive review. Surv Ophthalmol 64(5):619–638. https://doi.org/10.1016/j.survophthal.2019.04.006 - DOI - PubMed